Efficacy, tolerability and safety of nebivolol in patients with hypertension and diabetes: A post-marketing surveillance study

European Review for Medical and Pharmacological Sciences

Volumn 14, Issue 9, 2010, Pages 749-758

  Van Bortel, Luc M ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

Diabetes; Glycaemic profile; Hypertension; Lipidic profile; Nebivolol

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CELIPROLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; NEBIVOLOL; PROPRANOLOL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; POSTMARKETING SURVEILLANCE; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

AGED; ANALGESICS; BENZOPYRANS; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL; DIABETES MELLITUS; ETHANOLAMINES; FEMALE; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NETHERLANDS; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 78649420574     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. EZZATI M, LOPEZ AD, RODGERS A, VANDER HOORN S, MURRAY CJ; COMPARATIVE RISK ASSESSMENT COLLABORATING GROUP. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347-1360.
2. KEARNEY PM, WHELTON M, REYNOLDS K, MUNTNER P, WHELTON PK, HE J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-223.
3. MANCIA G, DE BACKER G, DOMINICZAK A, CIFKOVA R, FAGARD R, GERMANO G, GRASSI G, HEAGERTY AM, KJELDSEN SE, LAURENT S, NARKIEWICZ K, RUILOPE L, RYNKIEWICZ A, SCHMIEDER RE, BOUDIER HA, ZANCHETTI A, VAHANIAN A, CAMM J, DE CATERINA R, DEAN V, DICKSTEIN K, FILIPPATOS G, FUNCK-BRENTANO C, HELLEMANS I, KRISTENSEN SD, MCGREGOR K, SECHTEM U, SILBER S, TENDERA M, WIDIMSKY P, ZAMORANO JL, ERDINE S, KIOWSKI W, AGABITI-ROSEI E, AMBROSIONI E, LINDHOLM LH, VIIGIMAA M, ADAMOPOULOS S, AGABITI-ROSEI E, AMBROSIONI E, BERTOMEU V, CLEMENT D, ERDINE S, FARSANG C, GAITA D, LIP G, MALLION JM, MANOLIS AJ, NILSSON PM, O'BRIEN E, PONIKOWSKI P, REDON J, RUSCHITZKA F, TAMARGO J, VAN ZWIETEN P, WAEBER B, WILLIAMS B; MANAGEMENT OF ARTERIAL HYPERTENSION OF THE EUROPEAN SOCIETY OF HYPERTENSION; EUROPEAN SOCIETY OF CARDIOLOGY. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.
4. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
5. SKYLER JS, BERGENSTAL R, BONOW RO, BUSE J, DEEDWANIA P, GALE EA, HOWARD BV, KIRKMAN MS, KOSIBOROD M, REAVEN P, SHERWIN RS; AMERICAN DIABETES ASSOCIATION; AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION; AMERICAN HEART ASSOCIATION. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009; 119: 351-357.
6. LINDHOLM LH, CARLBERG B, SAMUELSSON O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-1553.
7. WILLIAMS B, POULTER NR, BROWN MJ, DAVIS M, MCINNES GT, POTTER JF, SEVER PS, THOM SM; BHS GUIDELINES WORKING PARTY, FOR THE BRITISH HYPERTENSION SOCIETY. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. Br Med J 2004; 328: 634-640.
8. ROBERTS WC, BLACK HR, BAKRIS GL, MASON RP, GILES TD, SULKES DJ. The editor's roundtable: revisiting the role of beta blockers in hypertension. Am J Cardiol 2007; 100: 253-267.
9. BAKRIS GL, FONSECA V, KATHOLI RE, MCGILL JB, MESSERLI FH, PHILLIPS RA, RASKIN P, WRIGHT JT Jr, OAKES R, LUKAS MA, ANDERSON KM, BELL DS; GEMINI INVESTIGATORS. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292: 2227-2236.
10. GIUGLIANO D, ACAMPORA R, MARFELLA R, DE ROSA N, ZICCARDI P, RAGONE R, DE ANGELIS L, D'ONOFRIO F. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997; 126: 955-959.
11. SARAFIDIS PA, BAKRIS GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM 2006; 99: 431-436.
12. BAKRIS GL. Pharmacological augmentation of endothelium-derived nitric oxide synthesis. J Manag Care Pharm 2007; 13(5 Suppl): S9-12.
13. MOEN MD, WAGSTAFF AJ. Nebivolol: a review of its use in the management of hypertension and chronic heart failure. Drugs 2006; 66: 1389-1409; discussion 410.
14. AGABITI ROSEI E, RIZZONI D. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs 2007; 67: 1097-1107.
15. MONCADA S, HIGGS A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-2012.
16. BALDWIN CM, KEAM SJ. Nebivolol: in the treatment of hypertension in the US. Am J Cardiovasc Drugs 2009; 9: 253-260.
17. MCNEELY W, GOA KL. Nebivolol in the management of essential hypertension: a review. Drugs 1999; 57: 633-651.
18. PHARMA M. NEBILET® 5 mg tablets. 2007 [updated 2007; cited 2009 6th October]; Available from: http://emc.medicines.org.uk/medicine/9145/SPC/ Nebilet+5mg+Tablets/.
19. IGNARRO LJ. Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol. Cardiovasc Ther 2008; 26: 115-134.
20. GRASSI G, TREVANO FQ, FACCHINI A, TOUTOUZAS T, CHANU B, MANCIA G. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. Blood Press Suppl 2003; 2: 35-40.
21. VAN BORTEL LM, FICI F, MASCAGNI F. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. Am J Cardiovasc Drugs 2008; 8: 35-44.
22. IGNARRO LJ. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker. Blood Press Suppl 2004; 1: 2-16.
23. SAUNDERS E, SMITH WB, DESALVO KB, SULLIVAN WA. The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens (Greenwich) 2007; 9: 866-875.
24. FOGARI R, ZOPPI A, LAZZARI P, MUGELLINI A, LUSARDI P, PRETI P, VAN NUETEN L, VERTOMMEN C. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. J Hum Hypertens 1997; 11: 753-757.
25. KAISER T, HEISE T, NOSEK L, ECKERS U, SAWICKI PT. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens 2006; 24: 1397-1403.
26. SCHMIDT AC, GRAF C, BRIXIUS K, SCHOLZE J. Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: the YESTONO study. Clin Drug Investig 2007; 27: 841-849.
27. CELIK T, IYISOY A, KURSAKLIOGLU H, KARDESOGLU E, KILIC S, TURHAN H, YILMAZ MI, OZCAN O, YAMAN H, ISIK E, FICI F. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006; 24: 591-596.
28. MANCIA G, LAURENT S, AGABITI-ROSEI E, AMBROSIONI E, BURNIER M, CAULFIELD MJ, CIFKOVA R, CLÉMENT D, COCA A, DOMINICZAK A, ERDINE S, FAGARD R, FARSANG C, GRASSI G, HALLER H, HEAGERTY A, KJELDSEN SE, KIOWSKI W, MALLION JM, MANOLIS A, NARKIEWICZ K, NILSSON P, OLSEN MH, RAHN KH, REDON J, RODICIO J, RUILOPE L, SCHMIEDER RE, STRULJKER-BOUDIER HA, VAN ZWIETEN PA, VIIGIMAA M, ZANCHETTI A. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-2158.
29. ROSEI EA, RIZZONI D, COMINI S, BOARI G. Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study. Blood Press Suppl 2003; 1: 30-35.
30. MAZZA A, GIL-EXTREMERA B, MALDONATO A, TOUTOUZAS T, PESSINA AC. Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. Blood Press 2002; 11: 182-188.
31. VAN BORTEL LM, BULPITT CJ, FICI F. Quality of life and antihypertensive effect with nebivolol and losartan. Am J Hypertens 2005; 18: 1060-1066.
32. PESANT Y. MARC-AURÈLE J, BIELMANN P, ALAUPOVIC P, CARTIER P, BICHET D, THIBAULT G, LUPIEN PJ. Metabolic and antihypertensive effects of nebivolol and atenolol in normometabolic patients with mild-to-moderate hypertension. Am J Ther 1999; 6: 137-147.
33. WAEBER B, BURNIER M, BRUNNER HR. Compliance with antihypertensive therapy. Clin Exp Hypertens 1999; 21: 973-985.
34. AMBROSIONI E, LEONETTI G, PESSINA AC, RAPPELLI A, TRIMARCO B, ZANCHETTI A. Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy. J Hypertens 2000; 18: 1691-1699.
35. FARMER KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 1999; 21: 1074-1090.